ArticleCancer medicine2026
Ubiquitin-Specific Protease 45 Inhibits Lung Adenocarcinoma Ferroptosis by Regulating Ubiquitination and Stability of Glutathione Peroxidase 4.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Lung adenocarcinoma is the most common subtype of lung cancer and the leading cause of cancer-related mortality worldwide. Ferroptosis, a regulated form of cell death characterized by iron-dependent lipid peroxidation, has emerged as a promising therapeutic target for lung adenocarcinoma. However, the molecular mechanisms that control ferroptosis sensitivity remain unclear. In this study, we identified ubiquitin-specific protease 45 (USP45) as a critical suppressor of ferroptosis in lung adenocarcinoma cells. Systematic screening of ubiquitin-specific proteases revealed that USP45 robustly enhanced glutathione peroxidase 4 (GPX4) protein expression. Bioinformatics analysis indicates that USP45 is significantly upregulated in lung adenocarcinoma patient datasets from the GEO and TCGA databases. Immunohistochemical results from the HPA database further corroborate this finding. Concurrently, elevated USP45 expression in lung adenocarcinoma patients frequently portends an unfavorable prognosis. Functional assays showed that USP45 depletion sensitized lung adenocarcinoma cells to erastin-induced ferroptosis, leading to impaired viability, colony formation, survival, migration, and invasion, whereas USP45 overexpression conferred resistance to ferroptotic stress and rescued the malignant phenotypes. Mechanistically, USP45 interacts with GPX4 and removes its ubiquitin chains, thereby stabilizing the GPX4 protein. Overexpression of GPX4 rescued ferroptosis sensitivity in USP45-deficient lung adenocarcinoma cells, whereas GPX4 depletion abrogated the protective effect of USP45 overexpression, establishing GPX4 as a functional mediator of USP45 activity. Collectively, these findings reveal a previously unknown USP45-GPX4 axis that promotes ferroptosis resistance and tumor progression in lung adenocarcinoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.